scholarly journals The Association Between Triglyceride-Glucose Index as a Marker of Insulin Resistance and the Risk of Breast Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Sonar Soni Panigoro ◽  
Noorwati Sutandyo ◽  
Fiastuti Witjaksono ◽  
Nurjati Chairani Siregar ◽  
Ramadhan Ramli ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dose Response ◽  
Univariate Analysis ◽  
Control Group ◽  
Tyg Index ◽  
Cancer Group ◽  
Triglyceride Glucose Index ◽  
Increased Risk ◽  
Referral Hospitals ◽  
Breast Cancer Group

BackgroundThis study aims to evaluate the association and dose-response between triglyceride-glucose (TyG) index and breast cancer.MethodThis is a multicenter case-control study conducted in six public referral hospitals in Indonesia. Cases are individuals aged 19 years or above who were diagnosed with breast cancer within 1 year of diagnosis, based on histopathology and immunohistochemistry. Controls were recruited from corresponding hospitals. TyG index was determined by the formula: ln (fasting TG [mg/dl] × fasting glucose [mg/dl]).ResultsThere were 212 participants in the breast cancer group and 212 participants in the control group. TyG index was higher in patients with breast cancer (median 8.65 [7.38, 10.9] vs. 8.30 [7.09, 10.84], p < 0.001). When compared with TyG quartile of Q1, Q4 was associated with an OR of 2.42 (1.77, 3.31), p < 0.001, Q3 was associated with an OR of 1.53 (1.21, 1.93), p < 0.001, Q2 was associated with an OR of 1.39 (1.12, 1.73), p = 0.002 for the risk of breast cancer. The dose-response relationship was nonlinear (p < 0.001). On univariate analysis, smoking (OR 2.15 [1.44, 3.22], p < 0.001), use of contraception (1.73 [1.15, 2.60], p = 0.008), alcohol consumption (OR 2.04 [0.96, 4.35], p = 0.064), and TyG Index >8.87 (OR 3.08 [1.93, 4.93], p < 0.001) were associated with risk of breast cancer. Independently associated with increased risk of breast cancer included smoking (OR 1.93 [1.23, 3.01], p = 0.004), use of contraception (OR 1.59 [1.02, 2.48], p = 0.039), and TyG Index >8.87 (OR 2.93 [1.72, 4.98], p < 0.001)ConclusionTyG index was associated with breast cancer in a nonlinear dose-response fashion.

scholarly journals Circulating Plasma miRNA-21 as a Superior Biomarker Compared to CA 15-3: Assessment in Healthy Age Matched Subjects and Different Stage of Breast Cancer Patients

2020 ◽  
Vol 12 (2) ◽  
pp. 157-64
Author(s):  
Merlyna Savitri ◽  
Ugroseno Yudho Bintoro ◽  
Made Putra Sedana ◽  
Muhammad Noor Muhammad ◽  
Pradana Zaky Romadhon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Circulating Mirna ◽  
Cancer Group ◽  
Significant Difference ◽  
Median Level ◽  
Breast Cancer Group ◽  
Low Sensitivity ◽  
Plasma Mirna

BACKGROUND: Carbohydrate antigens 15-3 (CA 15-3) is a conventional tumor marker in breast cancer, with low sensitivity and specificity. MicroRNA (miRNA)-21 showed its stability in circulation and could serve as powerful biomarker. The aim of this study was to evaluate miRNA-21 as breast cancer biomarker compared to CA 15-3 in Indonesian population.METHODS: Circulating plasma miRNA-21 expression was measured using qRT-PCR in 49 patients at various stages of breast cancer and 16 healthy controls. The relative expression value of miRNA-21 was calculated using 2-ΔΔCt. Meanwhile, CA 15-3 was quantified using electrochemiluminescence immunoassay (ECLIA) methods. The results of miRNA-21 and CA 15-3 plasma circulating expression were compared with controls at each stage and between stages of breast cancer.RESULTS: CA 15-3 median level in breast cancer group was 1.60 times higher compared to control group (p=0.019), 21.00 m/mL and 13.05 m/mL, respectively. Median miRNA-21 expression in breast cancer group was elevated 4.92 folds compared to control group (p=0.001), 4.43 and 0.90, respectively. There was no significant difference of CA 15-3 level between controls and all stages of breast cancer group. CA 15-3 cut-off value was 15.05 m/mL (p=0.016) with 59.2% sensitivity and 62.5% specificity. Meanwhile, there was a significant difference of miRNA-21 expression between controls and most stages of breast cancer group. Circulating miRNA-21 expression cut-off value was 2.07 (p=0.000) with 91.8% sensitivity and 87.5% specificity.CONCLUSION: Circulating miRNA-21 expression and CA 15-3 levels were significantly increased in breast cancer group compared to control group. The miRNA-21 expression increased consistently with breast cancer stage progression. miRNA-21 could serve as superior biomarker compared to CA 15-3.KEYWORDS: biomarker, breast cancer, circulating plasma, liquid biopsy, miRNA-21

scholarly journals Emotional Dysregulation Mechanisms in Psychosomatic Chronic Diseases Revealed by the Instability Coefficient

2020 ◽  
Vol 10 (10) ◽  
pp. 673
Author(s):  
Cristina Ciuluvica (Neagu) ◽  
Paolo Amerio ◽  
Ioan Valeriu Grossu
Keyword(s):  
Breast Cancer ◽  
Chronic Disease ◽  
Chronic Diseases ◽  
Control Group ◽  
Blood Cancer ◽  
Cancer Group ◽  
Emotional Vulnerability ◽  
Breast Cancer Group ◽  
Healthy Persons ◽  
Instability Coefficient

In the present work, we analyzed some emotional mechanisms (emotion dysregulation—ED, negative affect—NA, and emotional vulnerability) involved in chronic diseases by means of an interdisciplinary approach. We started from the conceptualization of emotions as a complex dynamic system that can be investigated and understood within a framework inspired by Chaos Theory. An “instability coefficient” Δ was computed to analyze ED mechanisms, NA, and emotional vulnerability in different disease groups (blood cancer, breast cancer, hypertension) as well as in healthy persons. This coefficient, recently defined by our group, computes the Euclidian distance between the pairs of vectors whose components are similar or reverted items of a test measuring ED. The emotional and somatic systems were considered as two complex dynamical systems in interaction. Due to this interaction, and as a result of the laws of complexity, a small perturbation in an inner state of the emotional system could generate an important reaction in the somatic system in time. The emotional vulnerability reflected by high values of Δ was associated with the chronic disease condition. The differences between illness groups and healthy persons, as well as between the three disease groups in Δ values, were analyzed. The results showed that there were significant differences between the chronic disease groups in Δ values. The most highly significant differences in Δ values were reported between the breast cancer group and the healthy group on one hand and between the breast cancer group and the blood cancer group on the other hand. The less significant differences in Δ values were noticed between the hypertension group and the control group. Δ was significant in predicting ED and NA. Compared to the classical approaches, the original contribution of our research is that these results encourage us to propose this interdisciplinary method of assessment as a challenging, valid tool of investigation and understanding of complex phenomena that occur in the emotional and somatic system.

Comorbidities in Medicare patients with and without breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 6533-6533
Author(s):  
M. Danese ◽  
C. O'Malley ◽  
D. Kim ◽  
K. Lindquist ◽  
M. Gleeson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patient ◽  
Diagnostic Testing ◽  
International Classification Of Diseases ◽  
Incidence Rates ◽  
Diagnostic Process ◽  
Cancer Group ◽  
Increased Risk ◽  
Classification Of Diseases ◽  
Breast Cancer Group

6533 Background: Patients with comorbidities may be at increased risk for adverse effects from treatment. We used the SEER-Medicare linked dataset to see if patients with breast cancer had a higher prevalence and subsequent incidence (after diagnosis) of comorbid conditions compared to patients without breast cancer. Methods: We selected all women with breast cancer across all stages, diagnosed from 1998–2002 with follow up through 2005. Patients were at least 66 years old with at least 12 months of non-HMO Medicare coverage prior to diagnosis. One non-cancer patient was matched to each breast cancer patient on sex and county of residence, and was assigned the cancer diagnosis date of her matched subject. Comorbidities were identified through groups of comorbidity-specific International Classification of Diseases, 9th revision (ICD-9) codes used in Medicare claims. Claims only for diagnostic testing were excluded, and outpatient-based diagnosis codes were required to be present at least twice with at least 30 days in between to be included. Prevalence at baseline (%) and incidence rates (per 1,000 person-years) and their 95% confidence intervals were calculated for each comorbidity. Rates in the non-cancer group were standardized to the age and race distribution of the breast cancer group to control for potential confounding. Results: 52,977 cancer patients met the inclusion criteria. See table for prevalence and incidence estimates. Conclusions: Physicians should be aware that patients with breast cancer have higher prevalence and subsequent incidence of these comorbidities compared to non-cancer subjects. These differences may be related to the diagnostic process, as well as to therapies used in cancer treatment. [Table: see text] [Table: see text]

Association of breast cancer and diabetes mellitus in Korean postmenopausal women

2020 ◽  
Author(s):  
Boram Kim ◽  
Jee Hye Han ◽  
Hee Yong Kwak ◽  
Kil Young Kwon ◽  
Junghwan Kim
Keyword(s):  
Breast Cancer ◽  
Diabetes Mellitus ◽  
Postmenopausal Women ◽  
Benign Breast Disease ◽  
Breast Disease ◽  
University Hospital ◽  
Control Group ◽  
Breast Clinic ◽  
Cancer Group ◽  
Increased Risk

Abstract Background: Diabetes mellitus has been associated with an increased risk of breast cancer. This association is, however, controversial, and not elucidated in Asia. This study aimed to determine the association between diabetes mellitus and breast cancer risk in Korean women.Methods: This retrospective study included subjects who underwent an ultrasound-localized needle-extracted biopsy to investigate questionable breast findings at the Eulji University Hospital breast clinic in Seoul, Korea, between 2000 and 2019. The medical records of the participants were reviewed to determine their age, diabetic status, and breast pathology findings. The participants were categorized into two groups, namely, the control group, that included those with benign breast disease; and, the breast cancer group. Logistic regression analyses were performed to assess the association between diabetes and breast cancer amongst pre- and post-menopausal participants.Results: A total of 1268 participants were included in this analysis. We found that diabetes was significantly associated with an increased odds of breast cancer (odds ratio [OR] 2.24; 95% confidence interval [CI], 1.76 to 2.84). Additionally, postmenopausal participants (aged ≥ 50 years) showed increased odds for breast cancer (OR 4.32; 95% CI, 3.37 to 5.53). The association between diabetes and breast cancer was significant, after adjusting for age, in the postmenopausal group (adjusted OR [aOR] 1.60; 95% CI, 1.09 to 2.35), but was not significant in the premenopausal group (aOR 1.10; 95% CI, 0.76 to 1.60).Conclusion: Diabetes was associated with increased odds of breast cancer compared to benign breast disease in postmenopausal women in Korea.

Gene polimorphisms and biological factors as possible predictors for patients with pleural metastatic breast cancer

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10671-10671
Author(s):  
A. Montes-Worboys ◽  
A. Romero ◽  
A. M. Casas ◽  
E. Arellano ◽  
J. M. Juan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
High Frequency ◽  
Metastatic Cancer ◽  
Metastatic Breast ◽  
Control Group ◽  
Biological Factors ◽  
Talc Pleurodesis ◽  
Cancer Group ◽  
Increased Risk

10671 Background: Pronosis of breast cancer varies widely in patients with similar clinical features. Therefore, we investigated other factors with possible prognostic value. The CYP17 gene has a polimorphism related to a increased susceptibility to breast cancer (single T; A1 allele to C; A2 allele). ( Mitrunen et al. Cancer Epidemiol Biomarkers Prev 2000,9;12;1343–8). On the other hand, it has been found in the MTHFR gene a common C-T substitution at nucleotide 677 that is associated with reduced enzyme activity and increased risk of breast cancer (Capmbell et al., Breast Cancer Research 2002;4,6:R14). Other genes such as GSTT1 and GSTM1 variant genotypes have a controversial association to breast cancer. We have analyzed the genotype and biological factors in a group of patients with pleural metastatic cancer of the breast and compared it to a control group of women with no cancer. Methods: Forty-six patients with breast cancer and forty women as controls were includes in the study. Age at diagnosis of the primary tumor, TNM staging, interval free of disease, estrogen and progesteron receptors, Ki67, p53 and Her-2neu expression were recorded, as well as survival from the time of diagnosis and polimorphism of CYP17, MTHFR, GSTT1 and GSTM1 genes. Results: Mean survival differed significantly between patients having pleural effusion as the first site of relapse as compared to those with other sites of relapse (28’9 vs 11’9 months, p = 0’004). A high Ki67 expression correlated best with longer survival after talc pleurodesis. We detected a high frequency in the CYP17 A2 variant genotype in patients with metastatic breast cancer compared to the control group. As for MTFHR gene, we found a high frequency for the T/T genotypes variant in breast cancer group. No significant differences between control and cancer group were found in either GSTT1 and GSTM1 gene variations. Conclusions: Genotype and biological factors, such as factors investigated in this study, play an important role as predictors for patients with pleural metastatic breast cancer. No significant financial relationships to disclose.

scholarly journals Determination Oxidant - Antioxidant Enzyme and some Trace Elements in Breast Cancer in Baghdad City

2014 ◽  
Vol 11 (2) ◽  
pp. 350-357
Author(s):  
Baghdad Science Journal
Keyword(s):  
Breast Cancer ◽  
Trace Elements ◽  
Control Group ◽  
Cancer Group ◽  
Iron Copper ◽  
Breast Cancer Group ◽  
Group A ◽  
Group B ◽  
High Level ◽  
Breast Group

level of effectiveness of Glutathione - S - Transferees (GST), Glutathione peroxides (GPX),Malondialdehyde (MDA) the product of lipid peroxidation and some trace elements ( zinc,seleinum,iron ,copper ) had been measured in sera of (50) women with breast disease.which had been divided to : Control group (25),The first group (A) benign breast tumors (25),the second group (B) breast cancer (25). The results showed a clear moral high level of Glutathione - S - Transferees (GST), Glutathione peroxidase (GPX) , and Malondialdehyde (MDA) level in breast cancer group while a slight increase were observed in the levels of these enzymes and(MDA) in benign breast group. A significant reduction was evident in the levels of selenium and zinc when compared with the control group while there were an increase in levels of sera copper , iron in the breast cancer group. As in (tissue) group of breast cancer found a rise in the level of selenium, zinc, copper, iron, compared with (serum) of breast cancer.

Risk of cancer treatment-related osteoporosis and fractures among women with breast cancer receiving aromatase inhibitors

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 557-557 ◽  
Author(s):  
B. Mincey ◽  
M. Duh ◽  
S. Thomas ◽  
E. Moyneur ◽  
M. Marynchencko ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Relative Risk ◽  
Bone Loss ◽  
Aromatase Inhibitors ◽  
Univariate Analysis ◽  
Estrogen Therapy ◽  
Control Group ◽  
Estrogen Production ◽  
Increased Risk ◽  
Risk Of Cancer

557 Background: Aromatase inhibitors (AIs) are a novel hormonal therapy for breast cancer. However, AIs can cause bone loss by blocking estrogen production. This study aims to assess the association between AIs and treatment-related bone loss in a large managed care population of women with breast cancer. Methods: Using medical and pharmacy claims data from over 5 million beneficiaries between 01/01/1998 and 01/31/2005, we identified 12,368 patients with ≥ 2 breast cancer claims in a 6-month period, who also had no bone metastasis and no prior osteoporosis or fracture claims. Patients who received anti-estrogen therapy were also excluded to remove the protective confounding effects. 1,354 patients receiving an AI (anastrozole, exemestane, letrozole) were compared to 11,014 controls who did not receive an AI with respect to their risk of bone loss. The observation start date for the AI and control groups was defined as the service date of the first AI claim and breast cancer claim, respectively. The bone loss endpoints analyzed were osteoporosis (including osteopenia) and clinical fractures. Results: The univariate analysis found that the prevalence of osteoporosis was 8.7% in the AI group vs. 7.1% in the control group, resulting in a statistically significant relative risk of 1.3 (95% CI=1.1–1.6, p=0.01). The prevalence of bone fracture was also statistically significantly elevated in the AI group compared to the controls (13.5% vs. 10.3%) with a relative risk of 1.4 (95% CI=1.2–1.6, p=0.001). Multivariate Cox proportional hazards regressions showed that after adjusting for age and comorbidities, the risk of bone loss remained statistically significantly higher in the AI group than the non-AI group, with 27% (95% CI=4%-55%, p=0.02) and 21% (95% CI=3%-43%, p=0.02) increase in the risk of osteoporosis and fractures, respectively. Conclusions: This retrospective longitudinal analysis of a large cohort of breast cancer patients corroborates previous findings from smaller clinical trials and demonstrates that AI therapies carry an increased risk of bone loss. Monitoring and treatment management strategies to alleviate bone loss risk are warranted in women receiving AI for breast cancer. [Table: see text]

scholarly journals Adiponectin Level in Women with Breast Cancer

2017 ◽  
Vol 2 (4) ◽  
pp. 91-94
Author(s):  
Fatemeh Homaee ◽  
Kamran Ghaffarzadehgan ◽  
Azar Aziminia ◽  
Hamideh Ghodrati ◽  
Azra Izanloo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adiponectin Level ◽  
Breast Cancer Incidence ◽  
Control Group ◽  
Future Studies ◽  
Cancer Group ◽  
Breast Cancer Group ◽  
Lower Adiponectin Level ◽  
Positive Effect ◽  
Healthy Females

Introduction: Adiponectin is one of the plasma protein derived from adipose tissue which has a positive effect on the metabolism of fat and lipid, resulting from its own receptors. Increase in body mass index (BMI) has a direct relationship with life length. Obesity has effects on secretion of some hormones related to adipokines. Adiponectin is an adipokine having an opposite relationship with insulin resistance and breast cancer. There is also an association between breast cancer incidence and obesity. Adiponectin level decreases in women affected by breast cancer and knowing this fact can help treat and prevent the cancer by giving adiponectin supplements. The present study compared the adiponectin levels in women affected by breast cancer and healthy females as a control group. Material and Method: In this study, 80 women with breast cancer and 80 healthy females as controls were selected and adiponectin level was compared between them. Result: Breast cancer group had higher BMI mean (28.77 ± 6.05) and lower adiponectin level in comparison to control group (p= 0.0001). Conclusion: Considering our findings, breast cancer risk is higher in women with higher BMI. Therefore, informing women in this regard could have a great effect on preventing this wide-spread disease. Taking adiponectin supplements as pills or injection could be a preventing step for breast cancer, which needs to be further cultivated in future studies.

Progesterone receptor (PROGINS) polymorphism and the risk of endometrial cancer development

2007 ◽  
Vol 17 (1) ◽  
pp. 229-232 ◽  
Author(s):  
M. G. Junqueira ◽  
I. D.C.G. Da Silva ◽  
N. C. Nogueira-De-Souza ◽  
C. V. Carvalho ◽  
D. B. Leite ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Progesterone Receptor ◽  
Receptor Gene ◽  
Population Based ◽  
Cancer Development ◽  
Control Group ◽  
Cancer Group ◽  
Increased Risk ◽  
Progesterone Receptor Gene ◽  
Risk Modifier

The progesterone receptor gene (PROGINS) has been identified as a risk modifier for benign and malignant gynecological diseases. The present case-control study is to evaluate the role of the PROGINS polymorphisms, as risk factor, for endometrial cancer development and to investigate the association between these genetics variants and clinical/pathologic variables of endometrial cancer. PROGINS polymorphism was examined in a total of 121 patients with endometrial cancer and 282 population-based control subjects, all located at the same area in São Paulo, SP, Brazil. The genotyping of PROGINS polymorphism was determined by polymerase chain reaction. The frequencies of PROGINS polymorphism T1/T1, T1/T2, and T2/T2 were 82.6%, 14.9%, and 2.5% in the endometrial cancer patients and 78.4%, 21.6%, and 0% in the controls, respectively. The χ2 test showed a higher incidence of the T2/T2 genotype in the endometrial cancer group subjects, these results were statistically different (P= 0.012). However, due to the fact that there were no women in the control group showing homozygosis for the allele T2, the correct evaluation of odds ratio could not be properly calculated. Regarding the clinical and pathologic findings observed within the group of patients with endometrial cancer, there was significant correlation between T1/T2 genotype and the presence of myoma (P= 0.048). No correlations were observed among the other variables. These data suggest that the PROGINS polymorphism T2/T2 genotype might be associated with an increased risk of endometrial cancer.

Sign in / Sign up

Export Citation Format

Share Document